BMC Gastroenterology最新文献

{"title":"Metabolic outcomes in non-alcoholic and alcoholic steatotic liver disease among Korean and American adults.","authors":"Yeongmin Kim, Tae Sic Lee, Chang-Myung Oh","doi":"10.1186/s12876-025-03687-4","DOIUrl":"10.1186/s12876-025-03687-4","url":null,"abstract":"<p><strong>Background: </strong>This study investigated the prevalence and causal relationships of chronic metabolic diseases (diabetes, hypertension, and dyslipidemia) with steatotic liver disease (SLD), specifically metabolically associated alcoholic liver disease (MetALD).</p><p><strong>Methods: </strong>We conducted a comprehensive analysis using cross-sectional data from the KNHANES from 2011 to 2021 and the NHANES from 1999 to 2020. Longitudinal data from 2001 to 2014 from the KoGES were used. Participants were categorized into the metabolic dysfunction-associated SLD(MASLD), MetALD, and ALD groups based on their hepatic steatosis index (HSI), including liver profiles, body composition, and diabetes, and alcohol consumption. Multivariable, including age and smoking status, logistic and Cox regression analyses were performed to assess the prevalence and incidence of chronic diseases.</p><p><strong>Results: </strong>In both the KNHANES and NHANES cohorts, an increased HSI was significantly associated with a higher prevalence of chronic metabolic diseases. Longitudinal data from the KoGES cohort showed that MASLD and MetALD were significant predictors of chronic metabolic disease in both men and women. MetALD showed a higher hazard ratio for the development of chronic metabolic diseases than MASLD in Cox regression analysis.</p><p><strong>Conclusions: </strong>This study highlighted the intertwined nature of SLD and metabolic health, with an emphasis on the role of MetALD. The significant association between MetALD and chronic metabolic diseases underscores the need for integrated management strategies that address both liver health and metabolic risk factors.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"110"},"PeriodicalIF":2.5,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11853905/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143490673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PD-1 inhibitor combined with chemotherapy or lenvatinib in advanced gallbladder cancer: a retrospective comparative study.","authors":"Hong-Yan Ma, Qin-Wen Tai, Hao Song","doi":"10.1186/s12876-025-03688-3","DOIUrl":"10.1186/s12876-025-03688-3","url":null,"abstract":"<p><strong>Background: </strong>Gallbladder cancer (GBC) is a refractory primary cancer. Some GBC patients are prone to recurrence even after surgical resection. In such cases, chemotherapy is the most common non-surgical treatment. The emergence of programmed cell death protein 1 (PD-1) inhibitors and targeted therapy have provided an additional option for those suffering from advanced tumors.</p><p><strong>Methods: </strong>This was a retrospective study involving patients with advanced GBC treated at the Shanghai Eastern Hepatobiliary Surgery Hospital between June 2019 and June 2022. The patients who received a PD-1 inhibitor (tislelizumab) with chemotherapy or with lenvatinib were retrospectively analyzed. The Response Evaluation Criteria in Solid Tumors (RECIST 1.1) was used as the efficacy evaluation standard. The overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and tumor marker CA199 were evaluated.</p><p><strong>Results: </strong>This study involved 61 patients with advanced GBC. Of these, 32 patients received tislelizumab and GS (gemcitabine and TS-1) chemotherapy, whereas 29 patients received tislelizumab and lenvatinib. For the Tislelizumab plus GS chemotherapy group, the median OS and PFS were 19.64 ± 11.81 (95% CI: 16.47-25.20) and 15.44 ± 13.42 (95% CI: 12.08-22.25) months, respectively. For the lenvatinib group, the OS and PFS were 13.06 ± 9.41 (95% CI: 9.72-16.63) and 10.34 ± 10.03 (95% CI: 6.56-14.13) months, respectively. The ORR and DCR were 59.38% and 81.3%, respectively, for the Tislelizumab plus GS chemotherapy group, which were significantly longer than those for the Tislelizumab plus Lenvatinib group. Treatment-related adverse events were similar between the groups.</p><p><strong>Conclusion: </strong>Tislelizumab combined with GS chemotherapy provides a safe and more efficient treatment option for advanced GBC patients.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"111"},"PeriodicalIF":2.5,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11849360/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143490677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A validation study of three early warning scores in early identification of gastric cancer patients with deteriorating condition after gastrectomy.","authors":"Xinli Shi, Huijuan Jie, Naifa Li, Qiongshan Liu, Yue Wang, Changquan Wu, Wenwen Jiang, Bolin Zhang, Shurong Lai, Honglu Xu","doi":"10.1186/s12876-024-03586-0","DOIUrl":"10.1186/s12876-024-03586-0","url":null,"abstract":"<p><strong>Objectives: </strong>Early warning scores (EWS) aim to rapidly identify patients at risk of critical illness or life-threatening events before deterioration occurs in clinical settings. This study aims to validate the ability of three commonly used early warning scores, namely the National Early Warning Score (NEWS), the Early Warning Score (SEWS), and the Modified Early Warning Score (MEWS), to identify patients with deterioration after gastric cancer resection in general wards.</p><p><strong>Methods: </strong>This retrospective case-control study included 110 patients who experienced clinical deterioration after gastrectomy for gastric cancer as case group, and 745 patients without deterioration as control group from a tertiary hospital in Guangdong Province, China. The discriminating ability (receiver operating characteristic curves), calibration (goodness-of-fit test) and net benefit (clinical decision curves) of the three EWS (NEWS, SEWS, MEWS) were explored to compare their early warning performance for patients at risk of post-operative deterioration.</p><p><strong>Results: </strong>MEWS (goodness-of-fit p = 0.123 > 0.05) and SEWS (goodness-of-fit p = 0.235 > 0.05) both demonstrate good calibration and good discrimination ability (AUC 0.710, 95% CI 0.654-0.766;AUC 0.756, 95% CI 0.701-0.811). In contrast, NEWS not only has good calibration (goodness-of-fit p = 0.283 > 0.05) but also exhibits the best discrimination ability among the three scoring systems (AUC 0.835, 95% CI 0.785-0.884) and the highest net benefit.</p><p><strong>Conclusion: </strong>Overall, NEWS may be more suitable for identifying gastric cancer patients at risk of post-operative clinical deterioration, as the early warning scoring model with best performance currently for post-gastrectomy observation.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"108"},"PeriodicalIF":2.5,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11849142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143490732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between lactate-to-albumin ratio and all-cause mortality in critically ill cirrhotic patients with sepsis: a retrospective analysis of the MIMIC-IV database.","authors":"Yuanji Ma, Lingyao Du, Lang Bai, Hong Tang","doi":"10.1186/s12876-025-03686-5","DOIUrl":"10.1186/s12876-025-03686-5","url":null,"abstract":"<p><strong>Background: </strong>The impact of lactate-to-albumin ratio (LAR) on mortality of critically ill cirrhotic patients with sepsis is scant.</p><p><strong>Methods: </strong>Critically ill cirrhotic patients with sepsis were obtained from the MIMIC-IV database (v3.0). Cox regression models alone and in combination with restricted cubic splines, generalized additive models and smoothed curve fitting were used to investigate the relationship between LAR and all-cause mortality.</p><p><strong>Results: </strong>A total of 1864 patients were included. The 30-day, 90-day, and 180-day all-cause mortality rates were 38.0%, 46.3%, and 49.5%, respectively. Higher LAR were significantly and nonlinearly associated with higher risks of 30-day, 90-day, and 180-day all-cause mortality (all adjusted HR = 1.17, P < 0.001). L-shaped associations between LAR and 30-day, 90-day, and 180-day all-cause mortality were observed, with an inflection point of 1.05 (P for log-likelihood ratio < 0.01). Compared with patients with LAR < 1.05, patients with LAR ≥ 1.05 had higher risks of 30-day, 90-day, and 180-day all-cause mortality (adjusted HR (95% CI): 1.48 (1.27-1.72), 1.44 (1.25-1.66), and 1.38 (1.21-1.57), respectively). No potential modifiers were found in the relationship between LAR and mortality.</p><p><strong>Conclusions: </strong>LAR was positively and nonlinearly associated with all-cause mortality in critically ill cirrhotic patients with sepsis. Thus, it could be used as a prognostic biomarker.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"112"},"PeriodicalIF":2.5,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11853895/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143490738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Big data analysis of influenza vaccination and liver cancer risk in hypertensive patients: insights from a nationwide population-based cohort study.","authors":"Chun-Chih Chiu, Wen-Rui Hao, Kuan-Jie Lin, Chun-Chao Chen, Tsung-Yeh Yang, Yu-Ann Fang, Tsung-Lin Yang, Yu-Hsin Lai, Ming-Yao Chen, Min-Huei Hsu, Cheng-Hsin Lin, Hsin Hsiu, Huan-Yuan Chen, Tzu-Hurng Cheng, Nai-Hsuan Chen, Ju-Chi Liu","doi":"10.1186/s12876-025-03665-w","DOIUrl":"10.1186/s12876-025-03665-w","url":null,"abstract":"<p><strong>Background: </strong>previous studies have indicated that influenza vaccination may be associated with reduced risks of certain types of cancer. However, the protective effect of influenza vaccination against primary liver cancer in individuals with hypertension remains unclear.</p><p><strong>Methods: </strong>In this cohort study, 37,022 patients over 55 years of age who received a diagnosis of hypertension at any time between January 1, 2001, and December 31, 2012, were enrolled from the National Health Insurance Research Database. The patients were divided into a vaccinated and an unvaccinated group. Categorical and continuous variables were analyzed using the chi-square test and t test, respectively, and the correlation between influenza vaccination and liver cancer in patients with hypertension was analyzed using time-varying COX model. Propensity score method was performed to reduce selection bias.</p><p><strong>Results: </strong>Compared with the unvaccinated group, the vaccinated group had a significantly lower incidence of liver cancer (hazard ratio = 0.56, 95% confidence interval = 0.46-0.64; p < .001). In addition, a protective effect was observed regardless of sex, age, or comorbidities. Besides, the association was dose-dependent which could be noted when patients were stratified based on the total number of vaccinations. The adjusted HRs for patients receiving 1, 2 to 3, and ≥ 4 vaccinations during the follow-up period were 0.60 (0.51-0.78), 0.48 (0.38-0.65), and 0.39(0.30-0.51), respectively.</p><p><strong>Conclusions: </strong>In summary, influenza vaccination is linked to a decreased risk of liver cancer in individuals with hypertension. However, unmeasurable confounders may have been present in the analysis.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"109"},"PeriodicalIF":2.5,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11849173/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143490750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic nutritional index is an effective prognostic and nutritional status indicator for cirrhosis.","authors":"Zichun Ao, Xi Chen, Weifang Zhu, Hui Long, Qiang Wang, Qingming Wu","doi":"10.1186/s12876-025-03599-3","DOIUrl":"10.1186/s12876-025-03599-3","url":null,"abstract":"<p><strong>Background and aim: </strong>Malnutrition is an important clinical feature of cirrhotic patients and is closely associated with prognosis. The prognostic nutritional index (PNI) is a measure of nutritional status. This study was conducted to clarify whether the PNI is related to the severity and prognosis of cirrhosis.</p><p><strong>Methods: </strong>In this study, we retrospectively analysed the clinical data of patients who were hospitalized with a primary diagnosis of liver cirrhosis from January 2020 to December 2023 at Tianmen Hospital affiliated with Wuhan University of Science and Technology. Cox regression was used to analyse the independent risk factors for prognosis in patients with decompensated cirrhosis, and the predictive value of the PNI for assessing cirrhosis severity and prognosis was analysed via receiver operating characteristic (ROC) curves.</p><p><strong>Results: </strong>A total of 513 patients with cirrhosis were included in the study. The patients were divided according to disease severity into compensated (28) and decompensated (485) groups, where the decompensated group consisted of the ascites-only group (63), the complications group (381), and the death group (41). The PNI [hazard ratio (HR) = 0.925, 95% confidence interval (CI): 0.858-0.997, P = 0.041] and platelet count (HR = 1.006, 95% CI: 1.002-1.01, P = 0.002) were found to be independent factors influencing poor prognosis in patients with decompensated cirrhosis. The PNI has predictive value for mortality in decompensated cirrhosis patients. Moreover, a significant disparity was observed in the PNI between the compensated and decompensated groups, and the PNI in the compensated group [47.03(42.85,51.50)] was markedly greater than that in the decompensated group [34.15(30.05,37.93)]. As the severity of the disease increased, the PNI progressively decreased in the ascites-only group [36.40 (32.15, 40.80)], the complication group [34.05 (30.08, 37.80)], and the death group [30.15 (27.05, 35.58)].The ROC curves revealed that the PNI had a high predictive value for decompensated cirrhosis [area under the curve (AUC) = 0.897] and the highest predictive value for mortality outcome (AUC = 0.943). This research also demonstrated that the PNI is strongly correlated with the occurrence and number of complications.</p><p><strong>Conclusion: </strong>The prognostic nutritional index is a good indicator of the severity and prognosis of cirrhotic disease and warrants clinical promotion.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"107"},"PeriodicalIF":2.5,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11849323/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143490766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced lung cancer inflammation index: a key predictor of hepatic steatosis and fibrosis severity.","authors":"Yajie Liu, Ruilin Wang","doi":"10.1186/s12876-024-03544-w","DOIUrl":"10.1186/s12876-024-03544-w","url":null,"abstract":"<p><strong>Background: </strong>The Advanced Lung Cancer Inflammation Index (ALI) reflects levels of systemic inflammation and nutrient metabolism in patients. However, The connection between ALI and hepatic steatosis and fibrosis remains unclear. This study aims to explore the potential association between ALI, the Controlled Attenuation Parameter (CAP), and Liver Stiffness Measurement (LSM), offering new perspectives for the prevention of hepatic steatosis and fibrosis.</p><p><strong>Methods: </strong>Using data from the National Health and Nutrition Examination Survey database spanning from 2017 to 2020, a cross-sectional study of 6591 participants aged 20 years and older was performed to assess the relationship between ALI and hepatic steatosis and hepatic fibrosis. Smooth curve fitting and generalized additive models were used to further evaluate whether there was a nonlinear association between ALI, CAP, and LSM, and threshold effect analysis was used to find the inflection point. A two-part linear regression model was applied to estimate threshold effects. Subgroup analysis and interaction were used to evaluate the potential association between ALI, CAP, and LSM. Furthermore, to verify the efficacy of ALI, we used ROC curves to compare ALI with fibrosis and nutritional markers (FIB-4 index, GNRI) that have been reported to be associated with liver disease.</p><p><strong>Results: </strong>The ALI levels in the MASLD and fibrosis 4 groups were considerably elevated than the control group, with statistical significance (P_MASLD<0.001, P_AHF =0.013). Multiple linear regression analyses indicated significant positive associations between ALI and its quartiles with both CAP[b(95%CI) _ALI=0.510(0.465,0.555), P<0.001] and LSM levels [b(95%CI) _ALI=0.011(0.009,0.013), P<0.001). There was a positive smooth curve fitting relationship between ALI and the levels of CAP and LSM, with threshold effect inflection points at 88.287 and 98.420 (P_{Log likelihood ratio}<0.001), respectively. ALI interacts with CAP in relation to gender [OR(95%CI)_female=0.095(0.039-0.150), OR(95%CI)_male=0.174(0.118-0.230), P_{for interaction}=0.044] and smoking [OR(95% CI)_{<100cigarettes in life}=0.086(0.035-0.137), OR(95% CI)_{>100cigarettes in life}=0.177(0.115-0.240), P_{for interaction}=0.023], and with LSM in patients with HL [OR(95% CI)_HL=0.014(0.008-0.019), P_{for interaction}<0.001].</p><p><strong>Conclusion: </strong>The findings suggest a positive correlation between elevated ALI levels and the levels of CAP and LSM. Maintaining ALI within an appropriate range may help mitigate the prevalence of hepatic steatosis and hepatic fibrosis.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"106"},"PeriodicalIF":2.5,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11849289/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143490735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors influencing the cure of pseudolithiasis: a retrospective study of 264 patients.","authors":"Leijiao Deng, Jie Deng","doi":"10.1186/s12876-025-03704-6","DOIUrl":"10.1186/s12876-025-03704-6","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To identify independent predictors of complete resolution in patients with pseudobiliary calculi and evaluate the effectiveness of different therapeutic strategies.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Clinical data were retrospectively analyzed from 264 patients with pseudobiliary calculi admitted to The First Hospital of Lanzhou University between January 2018 and December 2019. Patients were categorized into complete resolution group (n = 43) and persistent group (n = 221) based on discharge CT findings. Univariate and multivariate logistic regression analyses were performed to assess the impact of demographic characteristics, laboratory parameters, comorbidities, and therapeutic interventions on prognosis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Among 264 enrolled patients, 43 (16.29%) achieved complete resolution while 221 (83.71%) showed persistent calculi. Univariate analysis revealed significant differences between groups in gender (χ&lt;sup&gt;2&lt;/sup&gt; = 4.738, P = 0.030), concurrent cholecystitis (χ&lt;sup&gt;2&lt;/sup&gt; = 24.424, P &lt; 0.001), cholangitis (P = 0.001), viral hepatitis (χ&lt;sup&gt;2&lt;/sup&gt; = 3.957, P = 0.047), decompensated cirrhosis (χ&lt;sup&gt;2&lt;/sup&gt; = 6.827, P = 0.009), Age Groups (t=-2.232, P = 0.030), AST/ALT ratio (t = 6.340, P &lt; 0.001), and white blood cell count (t=-3.103, P = 0.002). Therapeutic interventions, including ceftazidime (χ&lt;sup&gt;2&lt;/sup&gt; = 11.21, P = 0.001), mezlocillin (P = 0.014), ornidazole (χ&lt;sup&gt;2&lt;/sup&gt; = 6.317, P = 0.012), and iodinated contrast media (χ&lt;sup&gt;2&lt;/sup&gt; = 5.271, P = 0.022), showed statistically significant differences between groups. Multivariable logistic regression analysis shows that acute cholecystitis [OR = 0.237, 95% CI (0.106-0.529), P &lt; 0.001], cholangitis [OR = 0.258, 95% CI (0.075-0.889), P = 0.032], and elevated white blood cell count [OR = 0.876, 95% CI (0.806-0.953), P = 0.002] are negatively associated with the resolution of pseudolithiasis. In contrast, the increase in the AST/ALT ratio [OR = 5.132, 95% CI(2.063-12.766), P &lt; 0.001] and the use of iodinated contrast agents [OR = 3.944, 95% CI(1.262-12.33), P = 0.018] are continuously positively correlated with pseudolithiasis.In addition, the use of ceftazidime [OR = 0.291, 95% CI (0.121-0.701), P = 0.006] and mezlocillin [OR = 0.045, 95% CI (0.004-0.531), P = 0.014] has a significant promoting effect on the resolution of pseudolithiasis. These findings provide a systematic analysis of potential predictive factors associated with the complete resolution of pseudobiliary stones, offering preliminary evidence for further optimization of personalized treatment strategies.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Our research indicates that, unlike chronic cholelithiasis, pseudolithiasis exhibits uniqueness and temporality. The underlying inflammatory gallbladder diseases and their treatments may facilitate the rapid resolution of pseudolithiasis, while factors such as viral hepatitis and decompensated cirrhosis may affect liver function and","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"105"},"PeriodicalIF":2.5,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11847377/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imaging features of epidermoid cysts in intrapancreatic spleen: a single center study of 24 patients.","authors":"Zehua Zhang, Feixiang Hu, Tiansong Xie, Yuqin Zhang, Qiang Zheng, Wei Liu, Lei Chen, Zhengrong Zhou","doi":"10.1186/s12876-025-03698-1","DOIUrl":"10.1186/s12876-025-03698-1","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to investigate the imaging features of epidermoid cysts within intrapancreatic accessory spleen (ECIPAS) to benefit the differential diagnosis of pancreatic cystic lesions.</p><p><strong>Methods: </strong>We retrospectively reviewed the clinical, radiological and pathological data of 24 patients with pathologically confirmed ECIPAS. All cases underwent abdominal contrast-enhanced computed tomography (CE-CT) scans, with 4 cases further undergoing magnetic resonance cholangiopancreatography (MRCP). The imaging features of the lesions were analyzed.</p><p><strong>Results: </strong>The majority of the patients were young to middle-aged with no apparent clinical symptoms. Over half of the masses exhibited circular, oval or unilocular architectures. On plain CT, the masses primarily displayed indistinct margins with an average diameter of 3.0 ± 1.1 cm. Nineteen lesions were situated in the pancreatic tail, 1 in the head, 1 in the head-body junction, and 3 in the body. In the arterial phases of enhanced CT scans, the lesions exhibited varying degrees of enhancement: slight enhancement (n = 11), significant enhancement (n = 5), and no discernible enhancement (n = 8) compared to pancreatic parenchyma. On MRCP scan, all four lesions showed hyperintense on T2-weighted imaging (T₂WI).</p><p><strong>Conclusion: </strong>ECIPAS is a rare benign lesion, with nearly half exhibiting slightly uneven enhancement on contrast-enhanced CT scans. Usually, the solid-portion-enriched lesions show similar enhancement to that of the spleen, aiding in the precise preoperative diagnosis. ECIPAS can manifest in various locations within the pancreas, including the tail, head, and body. Patients may benefit from improved quality of life by avoiding unnecessary surgeries.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"104"},"PeriodicalIF":2.5,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11847404/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dietary Inflammatory index and its association with fatty liver disease: a study in obese and non-obese populations.","authors":"Wei Fu, Junlong Zhao, GuoBin Cheng, Liang-Bi Xu, Linya Lyu, Yao Ding","doi":"10.1186/s12876-024-03585-1","DOIUrl":"10.1186/s12876-024-03585-1","url":null,"abstract":"<p><strong>Background: </strong>The worldwide incidence of non-alcoholic fatty liver disease (NAFLD) is a pressing health issue, with chronic inflammation critically influencing its development. The Dietary Inflammatory Index (DII) measures the inflammatory potential of one's diet. Our study aimed to investigate the association between DII and fatty liver disease in obese and non-obese individuals.</p><p><strong>Methods: </strong>Data from the 1999--2001 National Health and Nutrition Examination Survey (NHANES), encompassing 3456 adults aged 20 years and above, were utilized for the analysis. The multivariable analysis assessed the correlation between DII, NAFLD, and obesity while adjusting for demographic variables. The restricted cubic spline (RCS) method was also applied with restricted degrees of freedom to establish a non-linear relationship model between DII and NAFLD.</p><p><strong>Results: </strong>Our study demonstrated significant differences across DII tertiles in various demographic and clinical characteristics. An increase in t DII score by one standard deviation resulted in a 21% increase in the fatty liver risk. This association persisted after adjusting for age, sex, and other covariates. The risk of fatty liver disease increased significantly by 39% in the highest DII tertile. Regression analysis revealed a non-linear correlation between DII and the risk of fatty liver in obese adults. The subgroup analysis showed consistent findings across all subgroups, with particularly strong associations in specific demographic categories.</p><p><strong>Conclusions: </strong>Our findings suggest a significant association between the DII score and risk of fatty liver disease, particularly in obese individuals. These results underscore the potential role of diet-induced inflammation in pathogenesis of NAFLD.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"102"},"PeriodicalIF":2.5,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11846309/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143472261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}